Accession Number: | 0001562180-20-001250 |
Date: | 2020-02-12 |
Issuer: | CONSTELLATION PHARMACEUTICALS INC (CNST) |
Original Submission Date: |
VALENTINE KAREN
C/O CONSTELLATION PHARMACEUTICALS, INC.
215 FIRST STREET, SUITE 200
CAMBRIDGE, MA 02142
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-02-12 | M | 1,500 | a | $11.50 | 1,500 | direct | ||
COMMON STOCK | 2020-02-12 | S | 1,500 | d | $35.02 | 0 | direct | ||
COMMON STOCK | 2020-02-13 | M | 1,906 | a | $8.76 | 1,906 | direct | ||
COMMON STOCK | 2020-02-13 | M | 2,567 | a | $11.50 | 4,473 | direct | ||
COMMON STOCK | 2020-02-13 | S | 4,473 | d | $35.07 | 0 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 11.5 | 2020-02-12 | deemed execution date | M | 1,500 (d) | 2028-07-18 | common stock 1,500 | $11.50 | 123,039 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 11.5 | 2020-02-13 | deemed execution date | M | 2,567 (d) | 2028-07-18 | common stock 2,567 | $11.50 | 120,472 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 8.76 | 2020-02-13 | deemed execution date | M | 1,906 (d) | 2029-03-06 | common stock 1,906 | $8.76 | 26,144 | direct |
ID | footnote |
---|---|
f1 | these trades were made pursuant to a rule 10b5-1 trading plan. |
f2 | this transaction was executed in multiple trades at prices ranging from $35.00 to $35.04. the price reported above reflects the weighted average price. the reporting person hereby undertakes to provide upon request to the sec staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
f3 | this transaction was executed in multiple trades at prices ranging from $35.00 to $35.25. the price reported above reflects the weighted average price. the reporting person hereby undertakes to provide upon request to the sec staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
f4 | this option was granted on july 19, 2018 and is scheduled to vest as to 25% of the shares underlying the option on july 16, 2019, with the remainder vesting in equal quarterly installments through july 16, 2022, subject to continued service. |
f5 | this option was granted on march 7, 2019, and the shares underlying the option vest in equal quarterly installments through march 7, 2023, subject to continued service. |